BioXcel Therapeutics to Host Fourth Quarter & Full Year 2018 Financial Results and Business Update Conference Call
March 01, 2019 08:30 ET
|
BioXcel Therapeutics, Inc.
NEW HAVEN, Conn., March 01, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence...
BioXcel Therapeutics to Present at 2019 BIO CEO & Investor Conference
February 06, 2019 08:00 ET
|
BioXcel Therapeutics, Inc.
NEW HAVEN, Conn., Feb. 06, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), today announced that Dr. Vimal Mehta, Chief Executive Officer of BTI, will...
BioXcel Therapeutics Expands Indication for Lead Neuroscience Asset, BXCL501, to Treat Symptoms Associated with Opioid Drug Withdrawal
February 04, 2019 08:00 ET
|
BioXcel Therapeutics, Inc.
Clinical benefit observed in 10 of 10 patients; Human proof-of-concept established Provides further evidence of BXCL501’s mechanism of action Expands clinical advisory board with four additional...
BioXcel Therapeutics Reports Positive Human Proof-of-Concept Data for Acute Treatment of Agitation in Patients with Alzheimer’s Disease
January 03, 2019 08:00 ET
|
BioXcel Therapeutics, Inc.
Primary endpoint (safety and tolerability) met, with clinical benefit observed in 7 of 10 patients Proof-of-Concept established in agitated patients across multiple underlying disorders including...
BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL501 for Acute Treatment of Agitation
December 27, 2018 08:00 ET
|
BioXcel Therapeutics, Inc.
NEW HAVEN, Conn., Dec. 27, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), today announced that the U.S. FDA has granted Fast Track Designation for its...
BioXcel Therapeutics Doses First Subjects in Pharmacokinetic (Bioavailability) and Safety Study of BXCL501 for the Acute Treatment of Agitation
December 19, 2018 04:00 ET
|
BioXcel Therapeutics, Inc.
Data read-out expected in 1H 19 Results expected to support dose selection for anticipated registration trials in 2019 NEW HAVEN, Conn., Dec. 19, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics,...
BioXcel Therapeutics Announces FDA Acceptance of IND for Lead Neuroscience Candidate, BXCL501 for the Acute Treatment of Agitation
December 12, 2018 04:00 ET
|
BioXcel Therapeutics, Inc.
First-in-human pharmacokinetic (bioavailability) study with sublingual thin-film formulation Patient recruitment initiated and data read-out expected in 1H 19 Results to support dose selection for...
BioXcel Therapeutics to Present at BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference
December 03, 2018 06:00 ET
|
BioXcel Therapeutics, Inc.
NEW HAVEN, Conn., Dec. 03, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence...
BioXcel Therapeutics Reports Positive Results from Study in Agitated Schizophrenia Patients Supporting BXCL501 Clinical Development
November 14, 2018 04:00 ET
|
BioXcel Therapeutics, Inc.
Primary endpoint met, clinical benefit observed in 9 of 10 patients treated with intravenously (IV)-dosed Dexmedetomidine(Dex); no meaningful responses observed in placebo arm IV Dex well tolerated...
BioXcel Therapeutics Reports Third Quarter 2018 Quarterly Results and Provides Business Update
November 09, 2018 07:00 ET
|
BioXcel Therapeutics, Inc.
NEW HAVEN, Conn., Nov. 09, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence...